What is fatty liver disease?
Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the United States, affecting about one-quarter of the population.
If left untreated, it may progress into nonalcoholic steatohepatitis (NASH), an aggressive form of fatty liver disease, which is marked by liver inflammation and may progress to advanced scarring (cirrhosis) and liver failure.
Nonalcoholic Fatty Liver Disease (NAFLD)
A condition in which excess fat is stored in your liver.
Nonalcoholic Steatohepatitis (NASH)
A more severe form of NAFLD in which the buildup of fat in the liver causes inflammation and cell damage.
What puts you at risk for fatty liver disease?
If you meet any or all of these criteria, we recommend that you contact us for more information for a no-cost screening to see if you may be eligible for our paid research studies.
If you have type 2 diabetes or are prediabetic.
If you are overweight or obese
If you have other symptoms linked to metabolic syndrome such as: high cholesterol and high blood pressure
What is the status of your disease?
The liver is very resilient and capable of regenerating itself. If not taken care of, after many years it will reduce its ability to regenerate.
NAFLD is more common in people who have certain conditions, including obesity, type 2 diabetes, and metabolic syndrome.
Often NAFLD and NASH cause few or no symptoms. Certain health conditions—including obesity, metabolic syndrome, and type 2 diabetes— make you more likely to develop NAFLD and NASH.
Cirrhosis is a late stage of scarring (fibrosis) of the liver. Severe scarring has built up, making it difficult for the liver to function properly.
Scheduled for a liver biopsy?
Please watch our “Demystifying the Liver Biopsy” video with Dr. Gutierrez our in-house, board certified Hepatologist and Gastroenterologist
Hepatologist and Gastroenterologist
Meet Dr. Gutierrez
Dr. Julio Gutierrez is a renowned specialist in Hepatology and Gastroenterology and a board-certified physician in Internal Medicine, Transplant Hepatology, and Gastroenterology.
He is also a Principal Investigator on early phase studies of NASH and a member of the scientific team for the NASH PASS clinical research and patient registry program. He also participated in the HCV landmark clinical trials while at the Texas Liver Institute using Direct Acting Antivirals (DAAs), which ultimately revolutionized the care of patients with hepatitis C.
He is an internationally recognized speaker and has published more than 90 peer-reviewed publications in the field of liver disease. He earned his Medical Degree from Mount Sinai School of Medicine in New York City.
I’m interested, what’s next?
Sign Up Today
Each study has a set of criteria to determine a study participant’s eligibility. Please fill out our confidential online application.
Our highly trained study participant recruiters will review your application and contact you if you may be a fit for a current or future study. Incomplete applications may not be seen—please ensure all applicable fields are filled out.
Get to know us.
ProSciento’s clinical research facility is located 10 miles south of San Diego’s downtown area, 13 miles south of the San Diego International Airport, and 7 miles north of the US/Mexico border.
An on-site parking lot and parking garage are available and located within convenient access to public transportation. Additional transportation options may also be available at no-cost to study participants. Please ask your study participant recruiter for more information.
855 3rd Avenue,
Chula Vista, CA 91911
Monday – Friday
8:30 a.m. – 4:00 p.m.